Which assets fit our partnering priorities?
Screen by indication, mechanism, modality, and strategic fit. Investigate the shortlist against your criteria.
Opportunity shortlist
Keep biopharma research and working files current.
Put live intelligence behind research, medical affairs, BD, CI, and planning. Explore more opportunities, see what changes your position, and keep decision materials current.
The evidence changes
FDA approval · GSK
Nucala receives US approval for eosinophilic COPD.
Approved as add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.
View source 22 May 2025Sourced edits in your working files
Real source evidence.
Illustrative team files and assessments.
3 files updated
copd_competitive_review.pptxUpdated
regulatory_label_tracker.xlsxUpdated
Nucala · US COPD label
| Row | A | B |
|---|---|---|
| 1 | Label attribute | US label summary |
| 2 | FDA status | Under reviewApproved¹ |
| 3 | Patient population | Label pendingAdults with inadequately controlled eosinophilic COPD¹ |
| 4 | Treatment setting | Label pendingAdd-on maintenance¹ |
US COPD labelSources
medical_brief.docxUpdated
COPD regulatory update
Mepolizumab · US indication
Approved indication
Nucala is not yet approved for COPD in the US.Nucala is approved as add-on maintenance treatment for adults with inadequately controlled eosinophilic COPD.¹
Medical reviewCompare the approved population with the eligibility criteria in the pivotal COPD trials.
¹ Source linked1
Support each team’s research questions.
What changes our competitive position?
Compare trial evidence and competitor claims. Keep competitive landscape files current with source-linked edits.
Competitive landscape
Where can our program differentiate?
Benchmark the target product profile across efficacy, safety, population, and commercial context.
TPP benchmark
Which access conditions change the opportunity?
Research local HTA and reimbursement evidence alongside your market assumptions and internal insights.
Market access assessment
How does new evidence change our scientific view?
Compare publications, congress findings, and trial endpoints. Trace conclusions to source quotes and identify evidence gaps.
Evidence reviews · Scientific briefs
Which assumptions need another look?
Track clinical, competitive, and access developments against the assumptions behind forecasts and deal evaluations.
Assumption workbooks · Deal assessments
Work from current evidence in your team’s own way.
Start with your team’s questions, criteria, and documents. Use the same intelligence across research, monitoring, and maintained work.
01
Map
Your team brings
Your research questions & scope
Connect drugs, companies, targets, trials, and mechanisms.
A scoped landscape02
Compare
Your evaluation criteria
Research each asset in Smart Tables and extract study evidence in Document Grids.
An evidence comparison03
Assess
Internal insights & assumptions
Check claims against source quotes and surface gaps that affect the recommendation.
A cited assessment04
Brief
Your working files & templates
Build reports, presentations, and workbooks around the questions your team needs to answer.
Decision materialsLive intelligence throughout the work
Product & company sitesHTA & accessLiterature & congressesTrade press & advocacyTrials, filings & deals
Make the next decision from a current view.
- Monitor the question
- Watch for changes to differentiation, eligible populations, access conditions, and partnering fit.
- Maintain your working documents
- Upload or create files in a Maven project, then select the files to maintain. Review sourced edits, roll back changes, and download the current version.
- Use current evidence when you need it
- Research a new question, refresh a standing analysis, or run a saved workflow in your team’s format.
Respiratory portfolio watch
01
Which evidence changes the TPP benchmark?
02
Have eligible patient populations changed?
03
Which local access conditions affect positioning?
Watch for evidence that could change the assessment.
New endpoint results, comparative studies, or changes to access conditions.
Xcopd_tpp_benchmark.xlsx Updated
MEPOLIZUMAB · COPD01
Clinical differentiation benchmark
| Drug | Hospital / ED exacerbation benefit |
|---|---|
| Mepolizumab | Benefit establishedNot statistically confirmed in MATINEE¹ |
Evidence stays attached to the edit
¹ MATINEE · NEJMHospital / ED endpoint · Testing hierarchy
Earlier secondary endpoints failed in the testing hierarchy, so MATINEE could not establish statistical significance for the hospital/ED endpoint.
Sciurba et al. · N Engl J Med 2025;392:1710–1720Use the intelligence in your own tools.
Connect your assistants through MCP or build with the API and monitoring webhooks.
Explore integrationsKeep your research protected.
SOC 2 Type II, encryption, and no model training on customer data.
Review securityFit Maven to your team’s research process.
Can different functions use their own questions and criteria?
Yes. Medical affairs, BD, CI, research, strategy, planning, and finance teams can set their own scope, questions, and criteria. Scope research and monitoring by assets, indications, companies, and markets. Apply the team’s research questions, assessment criteria, and deliverable templates through custom workflows.
Can Maven work with the documents our teams already use?
Yes. Bring Word documents, PowerPoint presentations, or Excel workbooks, from scientific reviews and strategy decks to forecast assumptions and deal assessments. Define what each monitor should follow. Maven can apply relevant, sourced edits to selected documents, with a change history and rollback. Workflows can also produce the next review in your existing format.
Can our internal AI tools use the same intelligence?
Yes. Use Maven in the application, connect supported AI assistants through MCP, or build with the API and monitoring webhooks. Your internal tools can combine Maven’s external intelligence with the context and permissions in your environment.